Pharma’s Global Supply Chain Dilemma: Safeguarding IP and Managing Risk

The pandemic has cast a bright light on the IP and production capabilities of pharmaceutical companies—even while presenting general counsel and other C-suite leaders with new challenges in safeguarding IP, managing relations with regulators and securing supply chains.

Winston partners Reed Stephens and Cari Stinebower analyzed a real-world scenario in which a pharmaceutical company on the verge of a major new product launch is faced – at a critical moment – with an FDA inspection and the defection of a key executive to a rival, disruptions to its supply chain and potential implication in an international anti-corruption investigation. The webinar probed the broader legal and risk issues involved and outlined the steps companies can take to mitigate those risks.

Watch the presentation.

A webinar is a complimentary interactive seminar offered by Winston & Strawn LLP over the Internet. You'll watch and listen to the presentation at your own computer.

Winston & Strawn LLP is an accredited CLE provider in California, Illinois, New Jersey, New York, and Texas.

View all of our COVID-19 perspectives here. Contact a member of our COVID-19 Legal Task Force here.